Planned
BP44956
AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, RANDOMIZED, PHASE I STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7567132 AS SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Roche
- More information : NCT06537310
- Indication :
- Internal reference number : s69199
EIK1001-006
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Eikon Therapeutics
- More information : NCT06246110
- Indication :
- Internal reference number : s69605
HERTHENA - U31402-277
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Open-label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced or Metastatic Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Daiichi Sankyo
- More information : NCT06172478
- Indication :
- Internal reference number : s68502
PRISM-MEL-301 - IMC-F106C-301
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02: 01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Immunocore
- More information : NCT06112314
- Indication :
- Internal reference number : s68893
Ongoing
IMCGP100-203
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Immunocore
- More information : NCT05549297
- Indication :
- Internal reference number : s68071
REGENERON - R2810-ONC-1788
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Regeneron Pharmaceuticals
- More information : NCT03969004
- Indication :
- Internal reference number : s62852
V940-001
A Phase 3 Randomized, Double-blind, Placebo- and Active Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-risk Stage II-IV Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : MSD
- More information : NCT05933577
- Indiction :
- Internal reference number : s67845
Closed
ARRAY CMEK162X2110
A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Array BioPharma
- More information : NCT01543698
- Indication :
- Internal reference number : s55915
CA045-001
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Bristol-Myers-Squibb
- More information : NCT03635983
- Indication :
- Internal reference number : s61873
CLXH254C12201
A phase II randomized, open-label, multi-arm combinations in previously treated unresectable or metastatic BRAFV600 or NRAS mutant Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Novartis
- More information : NCT04417621
- Indication :
- Internal reference number : s64381
COMBI V MEK116513
A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : GSK
- More information : NCT01597908
- Indication :
- Internal reference number : s54395
IMBRELLA B BO40729
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Hoffmann-La-Roche
- More information : NCT03768063
- Indication :
- Internal reference number : s63702
IMSPIRE170 CO39722
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Spnosor : Hoffmann-La-Roche
- More information : NCT03273153
- Indication :
- Internal reference number : s60567
INITIUM UV1-202
Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Ultimovacs ASA
- More information : NCT04382664
- Indication :
- Internal reference number : s64047
KEYNOTE-006 MK3475-006
A multicenter, randomized, controlled, two-arm, phase III study to evaluate the safety and efficacy of MK-3475 compared to ipilimumab in patients with advanced melanoma
- Principal investigator : Prof. Dr. B. Beuselinck
- Sponsor : Merck
- More information : NCT01866319
- Indication :
- Internal reference number : s55059
KEYNOTE-587 MK3475-587
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
- Principal investigator : Dr. S. Woei-A-Jin
- Sponsor : Merck
- More information : NCT03486873
- Indication :
- Internal reference number : s62210
KEYNOTE-716 MK3475-716
Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Merck
- More information : NCT03553836
- Indication :
- Internal reference number : s62407
KEYVIBE - MK7684A-010
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : MSD
- More information : NCT05665595
- Indication :
- Internal reference number : s67214
MONETTE - D533AC00001
A Randomised, Open-Label, Phase 2 Study of Ceralasertib and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 inhibition
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : AstraZeneca
- More information : NCT05061134
- Indication :
- Internal reference number : s65853
MERKLIN2 4SC-202-3-2018
A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced, unresectable Merkel-Cell Carcinoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : 4SC AG
- More information : NCT04393753
- Indication :
- Internal reference number : s63675
1211_NOUS-PEV-01
An Open-Label, Multicenter, Non-Randomized, Dose confimiation and cohort Expansion Phase lb Study to Evaiuate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, a personalized genetic vaccine composed of a one GAd2O-PEV priming and 3 MVA-PEV boosting administration) with Pembroiizumab as per SoC PD1 inhibitor, in Patients with Stage lii (unresectable) / Stage IV Melanoma cancer or Stage IV NSCLC
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Pharm-Olam LLC Pharm-Olam LLC
- More information : NCT04990479
- Indication :
- Internal reference number : s64578
R2810-ONC-1620
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Regeneron
- More information : NCT03132636
- Indication :
- Internal reference number : s60241
TRILOGY CO39262
A phase III, double-blinded, randomized, placebo-controlled study of atezolizumab plus cimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Hoffmann-La-Roche
- More information : NCT02908672
- Indication :
- Internal reference number : s59701